CTIS2023-507304-32-00招募中1 期
THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+) - ANTES B+
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,028
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Female or male, 40-80 yrs. of age, Current/former smokers =10 pack-year, Diagnosis of COPD according to GOLD 2023 (post-BD FEV1/FVC<0.7 in the appropriate clinical context) with FEV1 post-BD 30-70% of the reference value, B+ phenotype 1. CAT=10 despite being on LABA-LAMA for =3 months, and 2. 1 moderate ECOPD in the previous year (treated with a short course of oral steroids and/or antibiotics), and 3. =150 blood Eos/?L (as determined by a single Eos measurement in the previous 12 months available in the medical record of the patient), A signed and dated written informed consent prior to study participation.
排除标准
- •GOLD E (=2 moderate or 1 severe ECOPD in the previous year), Long term antibiotic therapy (antibiotics are allowed for the short-term treatment of an exacerbation or for short term treatment of other acute infections during the study)., Systemic, oral, parenteral corticosteroids used for COPD and/or other diseases in the last 8 weeks before entering in the study (oral/systemic corticosteroids may be used to treat COPD exacerbations during the study)., Active neoplasm, Life expectancy < 1 yr., Current participation in other RCTs, Non-compliance: subjects at risk of non-compliance, or unable to comply with the study procedures., Any disease, disability, or geographic location that would limit compliance for scheduled visits., Known allergy to Trelegy® components (vilanterol, umeclidinium and/or fluticasone furoate) or inability to use the Ellipta® device., Women who are pregnant or lactating or are planning to become pregnant during the study., ICS treatment (or oral steroid for whatever reason) during the last 8 weeks, ECOPD during the last 8 weeks, Current diagnosis of asthma or documented history of asthma in the medical record of the patient according to the 2023 Global Initiative for Asthma (GINA) guidelines or other accepted guidelines, Other concomitant respiratory disease (e.g., bronchiectasis, lung fibrosis, lung neoplasm), Use of domiciliary long-term oxygen therapy or non-invasive ventilation, Alpha-1 antitrypsin deficiency, Unstable or life-threatening cardiac disease, including: 1. Myocardial infarction or unstable angina in the last 6 months 2. Unstable or life-threatening cardiac arrhythmia requiring intervention in the last 3 months. 3. NYHA Class IV Heart failure., Participation on Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study.
研究者
相似试验
招募中
2 期
To evaluate safety and performance of CREDENCEâ?¢ BRS Sirolimus Eluting BioResorbable Peripheral Scaffold System in subjects with de novo native peripheral artery lesions.CTRI/2017/01/007638Meril Life Sciences Pvt Ltd
进行中（未招募）
1 期
A Study of an Investigational Drug, Lumasiran (ALN-GO1) in Infants and Young Children with Primary Hyperoxaluria Type 1Primary Hyperoxaluria Type 1 (PH1)MedDRA version: 20.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2018-004014-17-FRAlnylam Pharmaceuticals, Inc.8
进行中（未招募）
1 期
A Study of an Investigational Drug, Lumasiran (ALN-GO1) in Infants and Young Children with Primary Hyperoxaluria Type 1Primary Hyperoxaluria Type 1 (PH1)MedDRA version: 20.1 Level: PT Classification code 10020703 Term: Hyperoxaluria System Organ Class: 10038359 - Renal and urinary disordersEUCTR2018-004014-17-GBAlnylam Pharmaceuticals, Inc.20
进行中（未招募）
1 期
A Study of an Investigational Drug, Lumasiran (ALN-GO1) in Infants and Young Children with Primary Hyperoxaluria Type 1Primary Hyperoxaluria Type 1 (PH1)MedDRA version: 20.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2018-004014-17-DEAlnylam Pharmaceuticals, Inc.20
已完成
不适用
A PROOF-OF-CONCEPT, OPEN LABEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE DOSES OF DSM265 IN ADULT PATIENTS WITH ACUTE, UNCOMPLICATED PLASMODIUM FALCIPARUM OR VIVAX MALARIA MONO-INFECTION OVER A 28-DAY-EXTENDED OBSERVATION PERIOD-B529 Plasmodium malariae malaria without complicationPlasmodium malariae malaria without complicationB529PER-044-14MMV Medicines for Malaria Venture,45